TBPH
Theravance·NASDAQ
--
--(--)
--
--(--)
TBPH fundamentals
Theravance (TBPH) released its earnings on Nov 10, 2025: revenue was 19.99M (YoY +18.51%), beat estimates; EPS was 0.07 (YoY +126.92%), beat estimates.
Revenue / YoY
19.99M
+18.51%
EPS / YoY
0.07
+126.92%
Report date
Nov 10, 2025
TBPH Earnings Call Summary for Q3,2025
- YUPELRI Record Performance: Q3 net sales $71.4M (15% YoY), hospital share at 21%, and $25M milestone on track with $54M needed in Q4.
- CYPRESS Trial Catalyst: Q1 2026 readout for ampreloxetine in MSA-related nOH, with $75M Q4 milestones and $100M 2026 TRELEGY target.
- Financial Strength: $333M cash, non-GAAP breakeven, and clinical data supporting long-term value.
- Strategic Focus: Execution on CYPRESS and YUPELRI growth, with potential capital return post-data.
EPS
Actual | -1.4 | -1 | -1.16 | -0.92 | -1.24 | -0.8 | -0.48 | -0.43 | -0.34 | -0.11 | 12.14 | -0.15 | -0.35 | -0.28 | -0.17 | -0.17 | -0.24 | -0.34 | -0.26 | -0.31 | -0.27 | 1.08 | 0.07 | |||||||||||
Forecast | -1.075 | -1.0357 | -1.0129 | -1.0213 | -1.0775 | -1.0225 | -0.5675 | -0.3257 | -0.11 | -0.0117 | -0.13 | -0.0767 | -0.2467 | -0.21 | -0.21 | -0.1475 | -0.2525 | -0.207 | -0.2309 | -0.1991 | -0.2058 | 0.6729 | -0.1279 | |||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -30.23% | +3.45% | -14.52% | +9.92% | -15.08% | +21.76% | +15.42% | -32.02% | -209.09% | -840.17% | +9438.46% | -95.57% | -41.87% | -33.33% | +19.05% | -15.25% | +4.95% | -64.25% | -12.60% | -55.70% | -31.20% | +60.50% | +154.73% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.86M | 15.01M | 18.26M | 18.73M | 14.26M | 12.91M | 13.19M | 14.95M | 13.20M | 11.05M | 12.45M | 14.65M | 10.42M | 13.75M | 15.69M | 17.57M | 14.50M | 14.26M | 16.87M | 18.75M | 15.39M | 26.20M | 19.99M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.13M | 19.64M | 18.58M | 19.87M | 17.27M | 15.41M | 14.40M | 13.49M | 14.40M | 12.49M | 11.81M | 15.40M | 13.70M | 15.29M | 15.40M | 17.57M | 13.96M | 15.38M | 15.68M | 17.03M | 15.57M | 25.93M | 19.96M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +9.56% | -23.60% | -1.72% | -5.76% | -17.44% | -16.18% | -8.38% | +10.81% | -8.34% | -11.56% | +5.43% | -4.90% | -23.98% | -10.06% | +1.89% | -0.06% | +3.87% | -7.28% | +7.61% | +10.13% | -1.20% | +1.00% | +0.15% |
Earnings Call
You can ask Aime
What were the key takeaways from Theravance's earnings call?What were the key takeaways from Theravance’s earnings call?What is the revenue and EPS growth rate for Theravance year over year?What factors drove the changes in Theravance's revenue and profit?What does Theravance do and what are its main business segments?What guidance did Theravance's management provide for the next earnings period?Did Theravance beat or miss consensus estimates last quarter?What is Theravance's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
